Hansel Aquino is an amateur mixed martial artist, and regardless of any accolades he may receive inside the cage throughout his career, the biggest victory of his life may have…

The post 5 weed products cancer survivor, MMA fighter, and comedian Hansel Aquino can't live without     appeared first on Weedmaps News.

Caryophyllene has a unique molecular structure. Specifically, it’s because it has a rare cyclobutene ring that isn’t found in other cannabis terpenes. When you consume cannabis high in caryophyllene, internally it easily binds to the CB2 receptors unlike THC which binds to the CB1 receptors. This is why THC causes a psychoactive effect but caryophyllene doesn’t produce a high. However, it will still enable you to feel its therapeutic benefits especially reducing inflammation.

Originally written by Will Fraser-Allen on Growth Business

Will Fraser-Allen, managing partner at Albion Capital, explains how venture capital trusts are driving growth in UK tech start-ups

DALLAS–(BUSINESS WIRE)–Pebble Global Holdings (aka “Pebble Life Sciences” or “Pebble”), a privately held Texas-based leader in non-psychotropic cannabinoid research for ... Read More

Taiwanese drug developer PharmaEssentia Corp. is fighting the enforcement of a €142 million ($161.1 million) arbitral award issued to Austrian pharmaceutical company AOP Orphan following an ill-fated deal to develop a new blood cancer treatment, arguing that it was denied due process in the arbitration.

Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive, and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and 12 months ended December 31, 2021.

Beyond Air, Inc. announced financial results for its third fiscal quarter ended December 31, 2021.

TOKYO, Feb 2, 2022 - (JCN Newswire) - Hitachi, Ltd. (TSE: 6501) has announced that "Shonan Kamakura Advanced Medical Center" at Shonan Kamakura General Hospital of Tokushukai Medical Group, where Hitachi's compact proton therapy system (hereafter, "the system") has been installed, has commenced treatment with the system on 31 January 2022. This is the first order for Hitachi's dedicated compact proton therapy system.
Shonan Kamakura Advanced Medical Center is a medical facility providing comprehensive cancer treatment, including advanced radiotherapy, built adjacent to the site of Shonan Kamakura General Hospital by Tokushukai Group Medical Corporation, which operates approximately 400 medical facilities and nursing homes throughout Japan. Until now, there have been no proton therapy facilities in Kanagawa Prefecture, where the center is located, but the compact proton therapy system, with its reduced footprint, makes it possible to install a proton therapy facility on a limited site close to the city center.

Features of the installed system

In response to the growing worldwide demand for smaller proton therapy systems, Hitachi has developed the proton therapy system, which is specifically designed for a single treatment room. The system is a compact proton therapy system which, by optimizing the layout of the machine, reduces the installation area to about 70% of that of conventional solutions, making it possible to install the system on a limited site in an urban area and reducing the cost and time involved in its installation. It is equipped with advanced technologies such as spot scanning irradiation technology, which allows the proton beam to be delivered according to the shape of the cancer, a 360degree rotating gantry with cone-beam CT(1) for high-precision positioning, and Real-time image Gated Proton Therapy (RGPT)(2), making it both compact and highly functional.

Hitachi is committed to accelerating the global development of particle therapy system and contributing to cancer treatment around the world, as well as to further expanding its healthcare services.

(1) Cone beam CT provides three-dimensional anatomical images of patients, at isocenter immediately prior to being treated. Information on the location of bone is obtained from traditional orthogonal x-rays and the motion of tumors is captured by RGPT. These are then combined with the ability to identify healthy tissue surrounding a tumor, particularly the location and shape of soft tissue, via Cone beam CT.
(2) RGPT allows real-time beam irradiation to the tumor while compensating for movement associated with respiration. This technology was collaboratively developed between Hokkaido University and Hitachi, and supported by the Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST) of the Japan Society for the Promotion of Science.

Overview of Particle Therapy

Particle Therapy is an advanced type of cancer radiotherapy. Protons extracted from hydrogen atoms, or carbon ions are accelerated up to 70% of the speed of light. This energy is concentrated directly on the tumor while minimizing radiation dose to surrounding healthy tissue. Particle therapy improves the quality of life for cancer patients since the patient experiences no pain during treatment and the procedure has very few side effects compared to that of traditional radiotherapy. In most cases, patients can continue with their normal daily activities while undergoing treatment.

About Hitachi, Ltd.

Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business. Hitachi is focused on strengthening its contribution to the Environment, the Resilience of business and social infrastructure as well as comprehensive programs to enhance Security & Safety. Hitachi resolves the issues faced by customers and society across six domains: IT, Energy, Mobility, Industry, Smart Life and Automotive Systems through its proprietary Lumada solutions. The company's consolidated revenues for fiscal year 2020 (ended March 31, 2021) totaled 8,729.1 billion yen ($78.6 billion), with 871 consolidated subsidiaries and approximately 350,000 employees worldwide. For more information on Hitachi, please visit the company's website at https://www.hitachi.com.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comHitachi, Ltd. has announced that "Shonan Kamakura Advanced Medical Center" at Shonan Kamakura General Hospital of Tokushukai Medical Group, where Hitachi's compact proton therapy system has been installed, has commenced treatment with the system on 31 January 2022.

In some cases, cancer survivors still have to deal with chronic pain. It can be so persistent that finding relief may feel hopeless, and it can also affect your overall quality of life. CBD is an excellent alternative to opioids for finding relief from pain; studies show that its powerful anti-inflammatory responses provide amazing relief from many kinds of pain. In a 2018 study, researchers found out that CBD was effective for reducing pain associated with cancer as well as neuropathic problems and fibromyalgia.

Chimeric antigen receptor (CAR) T cells have revolutionized cancer treatment. CARs use antibody-derived binding domains to redirect T cells to antigens expressed on the surface of cancer cells. However, the high affinity of most currently used CAR-binding domains results in excessive T-cell activation limiting CAR T-cell persistence and the inability to differentiate between antigen-high tumor cells and antigen-low healthy cells. We review recent data on the use of low-affinity CAR-binding domains and evaluate technologies and approaches to engineer and screen low-affinity antibody variants for CAR T-cell development.

The Alpha DaRT technology was initially developed by Tel Aviv University professors Itzhak Kelson and Yona Keisari.

The post Alpha Tau and MD Anderson to study Alpha DaRT for breast cancer treatment appeared first on Medical Device Network.

AOP Orphan has asked authorities in Germany to investigate allegedly deceptive statements a Taiwanese drug developer made during arbitration over an ill-fated deal to develop a new blood cancer treatment, including a proceeding in which the Austrian pharmaceutical company was awarded €140 million.